Trials / NCT04123626
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
Underway, not enrolling Phase 1 / Phase 2 RNA / antisense
- Sponsor
- ProQR Therapeutics
- Treatment
- QR-1123; Sham procedure
- Gene
- RHO
- Conditions
- Autosomal Dominant Retinitis Pigmentosa, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Disease, Retinitis, Vision Tunnel, Vision Disorders
- Ages
- 18 Years to no upper limit
- Enrollment
- 11 participants
- Started
- 2019-10-07
- Main results expected
- 2022-06-07
- Results posted
- Not yet
- Record last updated
- 2022-05-06
What the study is testing
This study evaluates the safety, tolerability and efficacy of QR-1123 injection in the eye (intravitreal; IVT) injections (one eye/unilateral) in subjects receiving a single dose or repeat doses. Single injections will be assessed in an open label way, and repeat injections will be assessed in a double-masked, randomized, sham-controlled fashion.
Where it runs
United States (5)
- Sue Anschutz-Rogers Eye Center, University of Colorado - Dept. of Ophthalmology, Aurora, Colorado
- VitreoRetinal Associates, Gainesville, Florida
- Shriners UK Ophthalmology - University of Kentucky, Lexington, Kentucky
- Casey Eye Institute, OHSU, Portland, Oregon
- Retina Foundation of the Southwest, Dallas, Texas